Curcumin ameliorates streptozotocin-induced heart injury in rats.
Heart failure (HF) is one of diabetic complications. This work was designed to investigate the possible modulatory effect of curcumin against streptozotocin-induced diabetes and consequently HF in rats. Rats were divided into control, vehicle-treated, curcumin-treated, diabetic-untreated, diabetic curcumin-treated, and diabetic glibenclamide-treated groups. Animal treatment was started 5 days after induction of diabetes and extended for 6 weeks. Diabetic rats showed significant increase in serum glucose, triglycerides, total cholesterol, low-density lipoprotein-cholesterol, very low density lipoprotein-cholesterol, nitric oxide, lactate dehydrogenase, cardiac malondialdehyde, plasma levels of interleukin-6, and tumor necrosis factor-alpha, and also showed marked decrease in serum high-density lipoprotein-cholesterol, cardiac reduced glutathione, and cardiac antioxidant enzymes (catalase, superoxide dismutase, and glutathione-S-transferase). However, curcumin or glibenclamide treatment significantly mitigated such changes. In conclusion, curcumin has a beneficial therapeutic effect in diabetes-induced HF, an effect that might be attributable to its antioxidant and suppressive activity on cytokines.
Department of Laboratory Sciences and Clinical Technology, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia; Department of Pharmacology and Toxicology, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr-City, Cairo, Egypt. oabosalem@yahoo.com.
Osama M
OM
Abo-Salem
Gamaleldin I
GI
Harisa
Tarek M
TM
Ali
El-Sayed M
el-SM
El-Sayed
Fatma M
FM
Abou-Elnour
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use*; D001786:Blood Glucose; D003474:Curcumin / Q000494:pharmacology / Q000627:therapeutic use*; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000139:chemically induced / Q000150:complications*; D005978:Glutathione / Q000378:metabolism; D005905:Glyburide / Q000494:pharmacology / Q000627:therapeutic use; D006333:Heart Failure / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D018836:Inflammation Mediators / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D009569:Nitric Oxide / Q000097:blood; D009929:Organ Size / Q000187:drug effects; D018384:Oxidative Stress; D017208:Rats, Wistar; D013311:Streptozocin; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D000975:Antioxidants; D001786:Blood Glucose; D018836:Inflammation Mediators; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D009569:Nitric Oxide; D013311:Streptozocin; D007770:L-Lactate Dehydrogenase; D005978:Glutathione; D003474:Curcumin; D005905:Glyburide
Curcumin; Cytokines; Diabetes; Heart Injury; Oxidative Stress; STZ